Johnson & Johnson (NYSE:JNJ) Shares Sold by Raiffeisen Bank International AG

Key Points

• Raiffeisen Bank International AG reduced its holdings in Johnson & Johnson by 18.9%, selling 5,791 shares during the first quarter, leaving it with 24,853 shares valued at approximately $4.07 million.
• Other institutional investors, including Northern Trust Corp and Bank of New York Mellon Corp, increased their stakes in Johnson & Johnson, indicating a mixed sentiment among investors.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding analyst estimates, with a significant quarterly revenue of $23.74 billion, marking a 5.8% year-over-year increase.

Raiffeisen Bank International AG lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,853 shares of the company's stock after selling 5,791 shares during the quarter. Raiffeisen Bank International AG's holdings in Johnson & Johnson were worth $4,069,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC increased its stake in Johnson & Johnson by 134.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in shares of Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after buying an additional 2,825,626 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Guggenheim reissued a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. UBS Group upped their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

JNJ stock traded up $0.82 during mid-day trading on Thursday, reaching $171.41. The company's stock had a trading volume of 9,268,506 shares, compared to its average volume of 9,076,776. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $158.53 and its two-hundred day moving average is $157.10. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $172.18. The stock has a market cap of $412.81 billion, a PE ratio of 18.33, a P/E/G ratio of 2.17 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.